IGF-1 LR3
Long R3 Insulin-like Growth Factor-1
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.
Complete Dosing Guide
Quick Reference
Administration Method
Subcutaneous injection, typically administered once daily in morning or post-workout
Step-by-Step Dosing Protocol
Dosing Guidelines
Research protocols typically employ 20-50 mcg daily via subcutaneous injection, administered as a single dose or divided into two doses (morning and post-workout). Starting protocols begin with 20-30 mcg daily for 7-14 days to assess tolerance, followed by potential increases of 10-20 mcg weekly up to 80-100 mcg maximum daily dose. Cycle length is standardized at 4-6 weeks active treatment followed by 3-6 weeks off-cycle to prevent receptor desensitization. Blood glucose monitoring is mandatory due to >40% hypoglycemia incidence. Injection sites should be rotated between abdomen, thighs, and upper arms to prevent tissue irritation.
Start small and go slow! Begin with 20-30 mcg once daily (about the size of a grain of salt) for your first 1-2 weeks to see how your body responds. If you tolerate it well, you can gradually increase by 10-20 mcg each week, but never exceed 80-100 mcg daily. Use it for 4-6 weeks, then take an equal break to reset your body's response. Always inject under your skin (not into muscle), rotating between your belly, thighs, and upper arms. Most importantly, check your blood sugar regularly since nearly half of users experience low blood sugar symptoms.
Mixing & Injection
IGF-1 LR3 is administered via subcutaneous injection using insulin syringes (29-31 gauge, 0.5-1.0 mL capacity). Reconstitution requires bacteriostatic water or sterile saline at 1 mg/mL concentration under aseptic conditions. Injection sites should be rotated systematically between abdomen (2 inches from navel), anterior thigh, and posterior upper arm to prevent lipodystrophy. Timing is critical: administer on empty stomach (minimum 2-hour fast) or within 30 minutes post-workout for optimal receptor sensitivity. Storage requires refrigeration at 2-8°C after reconstitution, with stability maintained for 14 days maximum.
IGF-1 LR3 is administered via subcutaneous injection using insulin syringes (29-31 gauge, 0.5-1.0 mL capacity). Reconstitution requires bacteriostatic water or sterile saline at 1 mg/mL concentration under aseptic conditions. Injection sites should be rotated systematically between abdomen (2 inches from navel), anterior thigh, and posterior upper arm to prevent lipodystrophy. Timing is critical: administer on empty stomach (minimum 2-hour fast) or within 30 minutes post-workout for optimal receptor sensitivity. Storage requires refrigeration at 2-8°C after reconstitution, with stability maintained for 14 days maximum.
Clinical Administration Guidelines
Injection Protocol
- •Subcutaneous injection once daily for 4-6 weeks
- •MANDATORY site rotation (abdomen, thigh, upper arm)
- •Morning on empty stomach or post-workout
- •CRITICAL: Empty stomach or have glucose source available
Monitoring Schedule
- •CRITICAL: Daily blood glucose monitoring
- •Weekly muscle measurement and progress photos
- •Monthly comprehensive metabolic panel
- •STOP if blood glucose <70 mg/dL or seizure symptoms
Dosage Calculator
Medical Disclaimer
IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.